Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P38484
UPID:
INGR2_HUMAN
Alternative names:
Interferon gamma receptor accessory factor 1; Interferon gamma receptor beta-chain; Interferon gamma transducer 1
Alternative UPACC:
P38484; Q9BTL5
Background:
Interferon gamma receptor 2 (IFNGR2) plays a pivotal role in immune response, partnering with IFNGR1 to form a receptor for interferon gamma (IFNG). This interaction is crucial for the activation of the JAK/STAT signaling pathway, essential for effective signal transduction. Known by alternative names such as Interferon gamma receptor accessory factor 1 and Interferon gamma transducer 1, IFNGR2's function is indispensable for mediating immunity.
Therapeutic significance:
IFNGR2's malfunction is linked to Immunodeficiency 28, a condition marked by impaired interferon-gamma mediated immunity, leading to susceptibility to mycobacterial diseases. Understanding the role of IFNGR2 could open doors to potential therapeutic strategies for treating or managing this autosomal recessive disease, which manifests early in life with severe infections.